inclusion criteria: * patient age 18 or above. * clinically suspected/proven covid-19. * requiring organ support with one or more of: * non-invasive or invasive ventilatory support * receiving infusion of vasopressor or inotropes or both. * no concomitant health problems that, in the opinion of the pi or designee in agreement with the treating clinician, would interfere with participation, administration of study drug or assessment of outcomes including safety.

inclusion criteria: * patient age 18 or above. * clinically suspected/proven covid-19. * requiring organ support with one or more of: * non-invasive or invasive ventilatory support * receiving infusion of vasopressor or inotropes or both. * no concomitant health problems that, in the opinion of the pi or designee in agreement with the treating clinician, would interfere with participation, administration of study drug or assessment of outcomes including safety.

inclusion criteria: - patient age 18 or above. - clinically suspected/proven covid-19. - requiring organ support with one or more of: - non-invasive or invasive ventilatory support - receiving infusion of vasopressor or inotropes or both. - no concomitant health problems that, in the opinion of the pi or designee in agreement with the treating clinician, would interfere with participation, administration of study drug or assessment of outcomes including safety.

inclusion criteria: - patient age 18 or above. - clinically suspected/proven covid-19. - requiring organ support with one or more of: - non-invasive or invasive ventilatory support - receiving infusion of vasopressor or inotropes or both. - no concomitant health problems that, in the opinion of the pi or designee in agreement with the treating clinician, would interfere with participation, administration of study drug or assessment of outcomes including safety.